The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.6004/jnccn.2015.0022 | DOI Listing |
Publication Analysis
Top Keywords
patients clear
12
clear cell
12
kidney cancer
8
nccn guidelines
8
cell renal
8
renal carcinoma
8
first-line treatment
8
cell carcinoma
8
cell
5
cancer version
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!